Ishita Rehman

Dr. Ishita Rehman

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2026 in The Microbe
Verified
Journal Article
Open access
ADAwantika Das
Awantika Das
RRRitwik Roy
Ritwik Roy
PGPiyasa Ghosh
Piyasa Ghosh
AMAlakesh Maity
Alakesh Maity
TBTamal Bhattacharjee
Tamal Bhattacharjee
PTProsun Tribedi
Prosun Tribedi

17 August 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
RFRongjie Fu
Rongjie Fu
Yalong WangYalong Wang
Yalong Wang
IRIshita Rehman
Ishita Rehman
EBElla Bedford
Ella Bedford
SSSana Sharif
Sana Sharif
HXHan Xu
Han Xu
Protein arginine methyltransferase 5 (PRMT5) is a synthetic lethal target in methylthioadenosine phosphorylase-deleted (MTAP-null) cancers. Second-generation methylthioadenosine (MTA)-cooperative PRMT5 inhibitors preferentially target MTAP-null cells while largely sparing MTAP-wildtype (MTAP-WT) cells, thereby improving tumor selectivity over first-generation PRMT5 inhibitors. Despite encouraging efficacy and safety signals in early clinical studies, the modest objective response rates (ORRs) observed with these inhibitors suggest that intrinsic or acquired resistance may limit their clinical benefit. Here, we investigated acquired resistance to the MTA-cooperative PRMT5 inhibitor BMS-986504/MRTX1719 in MTAP-null non-small cell lung cancer (NSCLC) cells and sought to identify therapeutic vulnerabilities that emerge upon resistance. Using multiple in vitro-derived resistant models, we found that acquired resistance was accompanied by cross-resistance to mechanistically distinct PRMT5 inhibitors. Notably, this phenotype was not fully explained by altered PRMT5 activity or changes in MTA levels. High-throughput drug screening of paired sensitive and resistant cells revealed increased sensitivity to MEK inhibitors following acquisition of MRTX1719 resistance in KRAS-wildtype NSCLC cells. Consistently, resistant cells exhibited rewired MAPK-related transcriptional programs. Together, these findings identify MEK inhibition as a reproducible collateral vulnerability associated with acquired MRTX1719 resistance in MTAP-null NSCLC models and support further evaluation of MEK inhibition as a potential treatment-switching strategy following resistance.

26 December 2025 in The Nucleus
Verified
Journal Article
Closed access
PPParamita Pramanik
Paramita Pramanik
TDTanaya Das
Tanaya Das
UPUdayan Pal
Udayan Pal
IRIshita Rehman
Ishita Rehman